Stock Research: Roivant Sciences

Independent stock analysis through peer comparison: Get the 360° View as an objective basis for stock decision-making and explore the detailed ranks.

Roivant Sciences

NasdaqGM:ROIV BMG762791017
14
  • Value
    20
  • Growth
    75
  • Safety
    Safety
    70
  • Combined
    8
  • Sentiment
    32
  • 360° View
    360° View
    14
Unlock
What factors are driving this 360° View?
Subscribe to View
Company Description

Roivant Sciences Ltd. is a biopharmaceutical company focused on improving the lives of patients by accelerating the development and commercialization of medicines that matter. The Company’s pipeline includes product candidates across various therapeutic areas, including immunology, oncology, hematology, and dermatology. Its pipeline includes IMVT-1402 and batoclimab, fully human monoclonal antibodies targeting FcRn in development across several IgG-mediated autoimmune indications; brepocitinib, a small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis and non-infectious uveitis; mosliciguat, an inhaled soluble sGC activator in development for pulmonary hypertension associated with interstitial lung disease, in addition to other clinical-stage molecules; and namilumab, is a fully human monoclonal antibody targeting granulocyte-macrophage colony stimulating factor, an inflammatory cytokine involved in inflammatory disorders such as sarcoidosis.

more
Index
NASDAQ
Similar Add to Watchlist Similar See Similar Stocks
The higher the 360° View, the better the stock performed against its peers, considering all metrics. The 360° View represents an average of the other 5 ranks and is then scaled to a rank from 1 to 100. The shaded values are illustrative only.
Last update: 18-Dec-2025.

Make Sense of the Ranks

The higher, the better. For every stock, we judge its performance against its peers and rank it on a scale of 1 to 100. These ranks are percentiles: a rank of 75 means the company outperforms 75% of its peers in that specific area. The higher the rank, the better the stock stacks up against its peers.

Detailed and Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history. Unlock the analysis.

Unlock Ranks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
20 45 7 24
Growth
75 1 100 67
Safety
Safety
70 69 38 66
Sentiment
32 40 70 26
360° View
360° View
14 25 55 32
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Analyst Opinions
95 82 89 87
Opinions Change
50 95 78 23
Pro Holdings
n/a 4 57 8
Market Pulse
19 23 11 43
Sentiment
32 40 70 26
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Value
20 45 7 24
Growth
75 1 100 67
Safety Safety
70 69 38 66
Combined
8 17 40 50
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Price vs. Sales (P/S)
100 100 2 2
Price vs. Earnings (P/E)
1 1 1 1
Price vs. Book (P/B)
35 64 6 61
Dividend Yield
1 1 1 1
Value
20 45 7 24
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Revenue Growth
100 1 90 86
Profit Growth
1 4 88 72
Capital Growth
90 11 94 51
Stock Returns
93 34 88 26
Growth
75 1 100 67
Unlock Similar Stocks

Unlock all 15 detailed ranks and historical data for 6,500+ stocks.

Subscribe to Unlock
Metrics Current 2024 2023 2022
Leverage
100 78 64 69
Refinancing
83 93 65 88
Liquidity
4 7 4 4
Safety Safety
70 69 38 66

Similar Stocks

Discover high‑ranked alternatives to Roivant Sciences and broaden your portfolio horizons.

Krka

LJSE:KRKG
Country: Slovenia
Industry: Pharmaceuticals
Size: Medium
Full Stock Analysis

Quilter

LSE:QLT
Country: United Kingdom
Industry: Asset Management & Custody
Size: Medium
Full Stock Analysis

Richter Gedeon Vegyészeti Gyár Nyilvánosan Muködo Rt.

BUSE:RICHTER
Country: Hungary
Industry: Pharmaceuticals
Size: Medium
Full Stock Analysis

Ipsen

ENXTPA:IPN
Country: France
Industry: Pharmaceuticals
Size: Large
Full Stock Analysis

Frequently Asked
Questions

The company has high growth and safe financing but is expensive (low Value Rank) and has low market sentiment. This is a warning that the stock may be too expensive. This is for an experienced growth investor willing to risk overpaying, but only after conducting thorough research on future growth potential.

Obermatt provides unbiased stock analysis as a completely independent third party. We have no conflicts of interest with individual stock titles. Our data-driven analysis is based on algorithms honed over twelve years, giving you analysis that is free from personal bias and conflicts of interest.

The 360° View Rank indicates a company's overall performance across all major financial and non-financial metrics tracked by Obermatt. A 360° View Rank of 75 means the company is more well-rounded than 75% of similar companies. A high score indicates that the company is strong across the board; it is attractively priced, growing sustainably, financially stable, and well-regarded by the market. Learn more.

Become an Obermatt subscriber and see all of the similar stocks here.

The Obermatt Advantage

Ready to Elevate Your Investing?
Get Started Today

Choose the Obermatt subscription that best fits your needs.


30-day money back guarantee. Your subscription will renew until you cancel it, which you can do at any time.

What Our Customers Say

See how Obermatt improved their investing: